Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET): A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)

#795

Introduction: OCT has shown antitumor activity and significantly prolonged time to tumor progression vs PBO in pts with metastatic midgut NET (PROMID).

Aim(s): To assess efficacy of OCT (30 mg q28d) in PBO+OCT arm of phase III RADIANT-2 study (a subgroup analysis).

Materials and methods: Progression-free survival (PFS; central review; cutoff Apr 2, 2010) and OS (cutoff Jun 13, 2013) were estimated using Kaplan-Meier method stratified by prior somatostatin analogue (SSA) use and primary tumor site.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Strosberg J

Authors: Strosberg J, Yao J, Bajetta E, Aout M, Bakker B,

Keywords: neuroendocrine tumors, octreotide LAR, PFS,